{"id":61721,"date":"2025-08-13T13:05:43","date_gmt":"2025-08-13T11:05:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/"},"modified":"2025-08-13T13:05:43","modified_gmt":"2025-08-13T11:05:43","slug":"wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/","title":{"rendered":"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System"},"content":{"rendered":"
\n

AUSTIN, Texas–(BUSINESS WIRE)–Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa\u2122 Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a major breakthrough in addressing sacroiliac joint dysfunction with enhanced biomechanical stability and procedural efficiency.<\/p>\n

<\/a>
<\/a><\/p>\n

\nDesigned to be implanted using a posterior, minimally invasive technique, panaSIa provides joint fixation through controlled expansion across the ilium and sacrum, offering immediate mechanical stability while preserving surrounding tissue. The implant\u2019s integrated graft chamber allows for post-expansion bone grafting without disengaging instrumentation, facilitating optimal fusion conditions and minimizing procedural complexity.<\/p>\n

\nThe first U.S. procedures are part of a limited commercial release taking place at select surgical centers ahead of full launch in Q4 2025.<\/p>\n

\n\u201cpanaSIa is unlike any SI fusion device currently available,\u201d said Aaron Calodney, MD, a nationally recognized leader in interventional pain medicine. \u201cThe implant expands to eliminate micro-motion, providing immediate stabilization. By slightly distracting the joint space, it may reduce pain by removing contact between the arthritic surfaces. It\u2019s simple, elegant, and biomechanically sound\u2014a truly next-generation solution for SI joint fusion.\u201d<\/p>\n

\nThe panaSIa system expands Wenzel Spine\u2019s portfolio of stand-alone expandable fusion technologies and reflects the company\u2019s long-term commitment to minimally invasive innovation and surgeon-driven design.<\/p>\n

\n\u201cThis launch is a defining milestone for Wenzel Spine,\u201d said William Wilson, CEO of Wenzel Spine. \u201cOur team has spent nearly two decades perfecting expandable device design, and panaSIa brings that legacy to a new clinical segment. We are proud to offer providers a differentiated, minimally invasive solution that transforms SI joint fusion with precision, control, and speed.\u201d<\/p>\n

\nAbout panaSIa\u2122 SI Fusion System<\/b><\/p>\n

\nThe panaSIa SI Fusion System is a posteriorly placed, expandable implant that transfixes the ilium and sacrum to immobilize the SI joint and promote fusion. It is offered in two sizes allowing for anatomical customization, while its streamlined instrumentation enables true MIS placement. The integrated expansion mechanism and post-expansion graft delivery system simplify the workflow and reduce operative time.<\/p>\n

\npanaSIa is available now in limited release and will be widely available in Q4 2025.<\/p>\n

\nAbout Wenzel Spine, Inc.<\/b><\/p>\n

\nHeadquartered in Austin, Texas, Wenzel Spine, Inc. is a privately held medical technology company committed to advancing the standard of care for spinal disorders through minimally invasive surgical innovation and data-driven solutions. Wenzel Spine’s technologies are used by leading spine and pain physicians across the country to streamline surgical procedures and improve patient outcomes.<\/p>\n

\nTo learn more, visit: www.wenzelspine.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nWilliam Wilson, Chief Executive Officer
\n
512.469.0600
\n
ceo@wenzelspine.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas–(BUSINESS WIRE)–Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa\u2122 Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61721","6":"format-standard","7":"category-industry"},"yoast_head":"\nWenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas–(BUSINESS WIRE)–Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa\u2122 Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-13T11:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250813069731\/en\/2551368\/22\/panaSIA_Blue_Green.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System\",\"datePublished\":\"2025-08-13T11:05:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/\"},\"wordCount\":466,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250813069731\\\/en\\\/2551368\\\/22\\\/panaSIA_Blue_Green.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/\",\"name\":\"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250813069731\\\/en\\\/2551368\\\/22\\\/panaSIA_Blue_Green.jpg\",\"datePublished\":\"2025-08-13T11:05:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250813069731\\\/en\\\/2551368\\\/22\\\/panaSIA_Blue_Green.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250813069731\\\/en\\\/2551368\\\/22\\\/panaSIA_Blue_Green.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/","og_locale":"en_US","og_type":"article","og_title":"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System - Pharma Trend","og_description":"AUSTIN, Texas–(BUSINESS WIRE)–Wenzel Spine, Inc., a medical device company pioneering minimally invasive surgical and analytic solutions for spinal disorders, today announced completion of first cases and the U.S. limited commercial launch of its novel panaSIa\u2122 Expandable SI Fusion System. panaSIa is the first expandable sacroiliac (SI) fusion implant cleared by the FDA and represents a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-13T11:05:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250813069731\/en\/2551368\/22\/panaSIA_Blue_Green.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System","datePublished":"2025-08-13T11:05:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/"},"wordCount":466,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250813069731\/en\/2551368\/22\/panaSIA_Blue_Green.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/","url":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/","name":"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250813069731\/en\/2551368\/22\/panaSIA_Blue_Green.jpg","datePublished":"2025-08-13T11:05:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250813069731\/en\/2551368\/22\/panaSIA_Blue_Green.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250813069731\/en\/2551368\/22\/panaSIA_Blue_Green.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/wenzel-spine-announces-limited-u-s-commercial-launch-and-first-cases-of-its-expandable-panasia-si-fusion-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Wenzel Spine Announces Limited U.S. Commercial Launch and First Cases of its Expandable panaSIa\u2122 SI Fusion System"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61721"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61721\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}